Bank of New York Mellon Corp purchased a new stake in Galapagos NV (NASDAQ:GLPG) during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 65,501 shares of the company’s stock, valued at approximately $3,634,000. Bank of New York Mellon Corp owned approximately 0.14% of Galapagos NV as of its most recent SEC filing.
A number of other large investors have also recently modified their holdings of the company. Wellington Management Group LLP increased its position in Galapagos NV by 28.5% in the first quarter. Wellington Management Group LLP now owns 800,199 shares of the company’s stock valued at $33,465,000 after buying an additional 177,656 shares in the last quarter. Deerfield Management Co. increased its position in Galapagos NV by 79.0% in the first quarter. Deerfield Management Co. now owns 327,626 shares of the company’s stock valued at $13,701,000 after buying an additional 144,626 shares in the last quarter. Alps Advisors Inc. increased its position in Galapagos NV by 47.6% in the second quarter. Alps Advisors Inc. now owns 64,775 shares of the company’s stock valued at $3,593,000 after buying an additional 20,901 shares in the last quarter. Landscape Capital Management L.L.C. increased its position in Galapagos NV by 114.7% in the first quarter. Landscape Capital Management L.L.C. now owns 17,389 shares of the company’s stock valued at $727,000 after buying an additional 9,288 shares in the last quarter. Finally, A.R.T. Advisors LLC bought a new position in Galapagos NV during the first quarter valued at approximately $547,000.
Shares of Galapagos NV (NASDAQ:GLPG) traded down 4.42% on Wednesday, reaching $65.32. The company had a trading volume of 157,536 shares. The firm’s market capitalization is $3.01 billion. Galapagos NV has a 52 week low of $37.03 and a 52 week high of $73.37. The stock’s 50 day moving average is $57.42 and its 200 day moving average is $52.05.
Several research analysts have recently commented on GLPG shares. Zacks Investment Research upgraded Galapagos NV from a “hold” rating to a “buy” rating and set a $67.00 price objective on the stock in a report on Wednesday, June 8th. Credit Suisse Group AG reiterated a “hold” rating and issued a $48.00 price objective on shares of Galapagos NV in a report on Friday, June 17th. Finally, Janney Montgomery Scott began coverage on Galapagos NV in a report on Tuesday, August 30th. They set a “buy” rating and a $64.00 price target on the stock. Two analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of €65.20 ($72.44).
About Galapagos NV
Galapagos NV is a Belgium-based biotechnology company. The Company’s activities are divided into two operating divisions: Research and Development (R & D) and Services. The R & D division is engaged in the discovery and development of small molecules. The Services division, offers target-to-drug discovery products and services to pharmaceutical and biotechnology companies and to patient foundations, encompassing target discovery and validation, screening and drug discovery through to delivery of pre-clinical candidates.
Want to see what other hedge funds are holding GLPG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Galapagos NV (NASDAQ:GLPG).
Receive News & Ratings for Galapagos NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galapagos NV and related companies with MarketBeat.com's FREE daily email newsletter.